Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation.
Langrehr
J M
JM
Department of Surgery, Virchow-Klinikum, Humboldt University Berlin, Germany.
Schneller
A
A
Guckelberger
O
O
Lohmann
R
R
Neumann
U
U
Jonas
S
S
Klupp
J
J
Settmacher
U
U
Knoop
M
M
Bechstein
W O
WO
Neuhaus
P J
PJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D015375:Receptors, Interleukin-2 / Q000276:immunology; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; C079843:inolimomab; D016559:Tacrolimus